<DOC>
	<DOCNO>NCT02677324</DOCNO>
	<brief_summary>This research study study target therapy possible treatment relapse refractory Waldenstrom 's Macroglobulinemia ( WM ) . This study use study intervention ABT-199 .</brief_summary>
	<brief_title>Study ABT-199 ( GDC-199 ) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia</brief_title>
	<detailed_description>This research study Phase II clinical trial . ABT-199 pill block BCL-2 , protein important survival WM cell . The purpose research study evaluate well study drug work safety ABT-199 single agent participant WM come back show response previous treatment . The FDA ( U.S. Food Drug Administration ) approve ABT-199 treatment disease .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Clinicopathological diagnosis Waldenstrom 's Macroglobulinemia meeting criterion treatment use consensus panel criterion Second International Workshop Waldenstrom 's macroglobulinemia ( Owen 2003 ; Kyle 2003 ) . Measurable disease , define presence serum immunoglobulin M ( IgM ) minimum IgM level &gt; 2 time upper limit normal institution require . Have receive least one prior therapy WM . Age ≥ 18 year . ECOG performance status &lt; 2 ( see Appendix A ) . Participants must normal organ marrow function ( growth factor give prophylactically establish eligibility ) define : Absolute neutrophil count &gt; 1,000/mm3 Platelets &gt; 50,000/mm3 Hemoglobin &gt; 8 g/dL Total bilirubin ≤ 1.5 mg/dL &lt; 2 mg/dL attributable hepatic infiltration neoplastic disease AST ( SGOT ) ALT ( SGPT ) &lt; 2.5X institutional upper limit normal Creatinine clearance ≥50 ml/min Not active therapy malignancy exception topical therapy basal cell squamous cell cancer skin . Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously complete abstinence heterosexual intercourse follow time period relate study : 1 ) participate study ; 2 ) least 28 day discontinuation study . Men must agree use latex condom sexual contact FCBP even successful vasectomy . FCBP must refer qualified provider contraceptive method need . Able adhere study visit schedule protocol requirement . Ability understand willingness sign write informed consent document . Any serious medical condition , laboratory abnormality , uncontrolled intercurrent illness , psychiatric illness/social condition would prevent participant signing informed consent form . Concurrent use anticancer agent treatment study agent . Prior exposure ABT199 BCL2 inhibitor . Prior ongoing clinically significant illness , medical condition , surgical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could affect safety patient , include symptomatic hyperviscosity ; alter absorption , distribution , metabolism excretion ABT199 ; impair assessment study result . Grade &gt; 2 toxicity ( alopecia ) continue prior anticancer therapy . Known CNS lymphoma . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen . New York Heart Association classification III IV heart failure . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , and/or Hepatitis C Virus ( HCV ) infection . Lactating pregnant woman . Inability swallow tablet . History noncompliance medical regimen . Unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>WM</keyword>
</DOC>